☰
The factory automation supplier is set to launch its brand in the Asian markets by 2019. The company has attained patents and certifications related to the machine automation essentials for smart factory systems. South Korea based IMT ....
Under the phase 2 trial approximately 90 patients with CLL will receive either ibrutinib or ibrutinib coupled with cirmtuzumab Oncternal Therapeutics, a biotechnology company, has reportedly announced opening of enrollment for patients suf....
This test would give opportunity to understand if NPS can induce immune response in patients with DCIS. The VADIS outputs could tell the company about potential synergies among standard therapies and NPS in the women suffering from DCIS.....
The Phase 1/2 study is a clinical trial of ET140202 ARTEMIS™ T-Cell therapy for the treatment of progressive hepatocellular carcinoma (HCC), one of the major types of liver cancer. Eureka Therapeutics, Inc., a biopharmaceutical ....
· Outputs would be shared globally with healthcare authorities at the next medical meeting. · While encouraging survival results were observed, the data isn’t mature enough and a follow-up would continue up until next p....
The state is suing T-Mobile’s $26.5 billion takeover of rival cellphone company Sprint. Texas has recently joined nearly a dozen American states that is filing a motion to stop T-Mobile’s acquisition of rival telecomm....
CEO Dr. Athena Countouriotis will participate in a question and answer session at the conference in Boston this month. Turning Point Therapeutics, Inc., a clinical-stage oncology company focused on developing novel drugs to address tr....
MRT5005 has been designed to address the primary cause of cystic fibrosis (CF) irrespective of genetic mutation Reports confirm that Translate Bio, an mRNA therapeutics company, has recently announced the interim results from a first-in-hu....
The series A funding of Minut raised $8 million. The added advantage offered is home monitoring with no hinderance to individual privacy of people living there. A Swedish startup company formed in 2014, Minut has reportedly developed a....
Novartis International AG, a Swiss-based pharmaceutical company recently announced results from Phase 3 PARAGON-HF trial in HFpEF (heart failure patients with preserved ejection fraction), investigating the efficacy & safety of sacubitr....
